Apatinib in Advanced Gastric Cancer: A Doubtful Step Forward

To the Editor: Li et al1 have recently reported the results of a phase III trial that evaluated apatinib treatment in patients with advanced gastric cancer who experienced disease progression after two or more lines of systemic therapy. The authors compared apatinib—a tyrosine kinase inhibitor that targets the vascular endothelial growth factor receptor-2 (VEGFR-2)—with placebo among 273 randomly assigned patients and reported an overall survival advantage in favor of the experimental treatment. This study represents an important step forward in gastric cancer research, as it confirms the value of targeting VEGFR-2 beyond the already available evidence that supports the use of ramucirumab, an anti-VEGFR-2 antibody, in the second-line setting.2,3 However, there are several potential pitfalls that may limit the value of these results.

With regard to patient characteristics, an imbalance in performance status (PS) distribution is evident, with an excess of patients with a PS of 0 in the experimental arm compared with placebo (27.3% v 16.5%). The authors conclude that this difference does not formally reach statistical significance, but, in our opinion, this could have had an unpredictable impact on overall survival. Indeed, PS is one of the main determinants of survival in advanced gastric cancer from first-line to third-line setting,4-6 and even a seemingly mild deterioration in the general condition, that is, a PS of 1 according to the Eastern Cooperative Oncology Group scale, might impair outcomes in such a fragile patient scenario.

In terms of safety, apatinib resulted in a not negligible rate of grade 3 to 4 hand-foot syndrome (8.5%), with approximately one grade 3 to 4 neutropenia. Is it really reasonable to conclude that apatinib “has a favorable safety profile in comparison with other antiangiogenic agents”?7 In the larger REGARD trial, single-agent ramucirumab resulted in a much lower rate of proteinuria (all grade, 4%), and grade 3 to 4 neutropenia and hand-foot syndrome were not reported.2,3 Whereas these adverse events are manageable when apatinib is administered as monotherapy, they may not suit well when apatinib is combined with cytotoxic agents used in gastric cancer, such as fluoropyrimidines and platinum compounds. With regard to cardiac safety, initial data with apatinib seems reassuring; however, comparisons with sunitinib and bevacizumab—as reported in the Discussion of the article by Li et al1 and for which we have greater knowledge about potentially severe cardiovascular events—seem at least premature. This is particularly true if we keep in mind that elderly patients (age >70 years) were excluded from the trial, the number of patients between age 65 and 70 years was limited (37 patients), and the median age in the two arms (age 58 years) is lower than that observed in routine practice.1 In the REGARD trial with ramucirumab, despite a similar median age in the enrolled patient cohorts, the upper age limit was 84 years and the number of patients age ≥ 65 years was greater (249 patients). Neither in the REGARD trial1 nor in the REGARD trial, did the age subgroup analyses report increased toxicity among older patients, with the exception of a relatively higher rate of grade ≥ 3 neutropenia in the REGARD trial.

Finally, no significant improvement in quality of life was noted for apatinib.7 Quality-of-life data for ramucirumab monotherapy have been recently published; ramucirumab proved to delay the worsening of symptoms and the deterioration of PS.8 It should be recognized that the population enrolled in the apatinib trial had a far more pretreated disease, but patient characteristics of PS, age, and number of metastatic sites seem comparable between trials.1,2

With an arguably increasing number of patients receiving ramucirumab in the second-line setting, it is difficult to anticipate the potential impact of apatinib in routine clinical practice. As these agents share the same target along the pathways that regulate tumor angiogenesis, the efficacy of apatinib in overcoming resistance to ramucirumab is unclear. Moreover, results with apatinib have been reported among Chinese patients. As a result of differences in the biologic background and treatment patterns between Eastern and Western patients with gastric cancer,9 other studies should be awaited to confirm these data outside Asia.

To conclude, apatinib is another arrow in the bow against gastric cancer. Future trials and, we hope, the identification of predictive biomarkers will ultimately tell us how far we can hurl our hope in this challenging struggle.

Lorenzo Fornaro, Enrico Vasile, and Alfredo Falcone
Azienda Ospedaliero-Universitaria Pisa, Pisa, Italy

Authors’ Disclosures of Potential Conflicts of Interest
Disclosures provided by the authors are available with this article at www.jco.org.

References
1. Li J, Qin S, Xu J, et al: Randomized, double-blind, placebo-controlled phase III trial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction. J Clin Oncol 22:2395-2403, 2004
2. Fuchs CS, Tomasek J, Yong CJ, et al: Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma ( REGARD): An international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 383:31-39, 2014
3. Wilke H, Muro K, Van Cutsem E, et al: Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): A double-blind, randomised phase 3 trial. Lancet Oncol 15:1224-1235, 2014
4. Chau I, Norman AR, Cunningham D, et al: Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer—pooled analysis from three multicenter, randomized, controlled trials using individual patient data. J Clin Oncol 22:2390-2403, 2004
5. Catalano V, Graziano F, Santini D, et al: Second-line chemotherapy for patients with advanced gastric cancer: Who may benefit? Br J Cancer 99:1402-1407, 2008
6. Shim HJ, Yun JY, Hwang JE, et al: Prognostic factor analysis of third-line chemotherapy in patients with advanced gastric cancer. Gastric Cancer 14:249-256, 2011
7. Fuchs CS, Tomasek J, Cho JY, et al: REGARD: A phase 3, randomized, double-blind trial of ramucirumab (RAM) and best supportive care (BSC) versus placebo (PL) and BSC in the treatment of metastatic gastric or gastrooesophageal junction (GEJ) adenocarcinoma following disease progression (PD) on first-line
Correspondence

platinum- and/or fluoropyrimidine-containing combination therapy: Age subgroup analysis. J Clin Oncol 32:5s, 2014 (abstr 4057)

8. Muro K, Bodoky G, Cesas A, et al: RAINBOW: A global, phase 3, double-blind study of ramucirumab (RAM) plus paclitaxel (PTX) versus placebo (PL) plus PTX in the treatment of advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma following disease progression on first-line platinum- and fluoropyrimidine-containing combination therapy—An age-group analysis. J Clin Oncol 33, 2015 (suppl 3, abstr 11)

9. Al-Batran SE, Van Cutsem E, Oh SC, et al: Quality-of-life and performance status results from the phase III RAINBOW study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated gastric or gastroesophageal junction adenocarcinoma. Ann Oncol 27:673-679, 2016

10. Yamada T, Yoshikawa T, Taguri M, et al: The survival difference between gastric cancer patients from the UK and Japan remains after weighted propensity score analysis considering all background factors. Gastric Cancer 19:479-489, 2016

DOI: 10.1200/JCO.2016.68.6931; published online ahead of print at www.jco.org on August 15, 2016.
AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

Apatinib in Advanced Gastric Cancer: A Doubtful Step Forward

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO’s conflict of interest policy, please refer to www.asco.org/rwc or jco.ascopubs.org/site/ifc.

Lorenzo Fornaro  No relationship to disclose

Enrico Vasile  No relationship to disclose

Alfredo Falcone  No relationship to disclose

© 2016 by American Society of Clinical Oncology